Company intelligence / Profile preview

MenoGeniX

Aurora, Colorado, United Statesmenogenix.com ↗

Ownership: Private
Development stage: Phase 1

Overview

MenoGeniX is developing MNGX-100, a non-hormonal, non-antidepressant therapy for menopausal hot flashes. The company has completed or is conducting Phase 1b/IIa trials with NIH SBIR grant support to evaluate safety and efficacy in women with natural or surgical menopause. No published results from later-stage trials are available yet.[5]

Therapeutic areas: Women's Health
Modalities: Protein therapeutics (specifically, a version of a naturally-occurring human blood protein)[5]Colony-stimulating factors[6]Biosimilars[6]
Industry: Biotech

Drug pipeline

1 asset

MNGX-100

Phase 1

Indications: Hot flashes, Vasomotor symptoms, Menopause symptoms

Partnerships

National Institute on Aging / NIH SBIR grant funding for clinical development[5].

Beyond the preview

Go deeper on MenoGeniX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MenoGeniX.

Explore the full profile